Benign biliary strictures: prevalence, impact, and management strategies

Michael Xiang Ma1,2, Vanoo Jayasekeran1, Andre K Chong1
1Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, Perth, WA 6150, Australia; 2Midland Physician Service, St John of God Midland Public Hospital, Midland, Perth, WA 6056, Australia

Abstract: Benign biliary strictures (BBSs) may form from chronic inflammatory pancreatobiliary pathologies, postoperative bile-duct injury, or at biliary anastomoses following liver transplantation. Treatment aims to relieve symptoms of biliary obstruction, maintain long-term drainage, and preserve liver function. Endoscopic therapy, including stricture dilatation and stenting, is effective in most cases and the first-line treatment of BBS. Radiological and surgical therapies are reserved for patients whose strictures are refractory to endoscopic interventions. Response to treatment is dependent upon the technique and accessories used, as well as stricture etiology. In this review, we discuss the various BBS etiologies and their management strategies.

Keywords: benign biliary stricture, endoscopic retrograde cholangiopancreatography, metal stent, plastic stent, stricture dilatation, chronic pancreatitis, liver transplantation, primary sclerosing cholangitis

Introduction

BBSs most often arise from postoperative or inflammatory etiologies. Surgery-related BBS most frequently results from LC, bile-duct surgery, and liver transplantation. The incidence of LC-related BS is ~0.5%, usually caused by direct surgical bile-duct injury, including thermal injury, scissors, ligatures, or clips. BSs that form following liver transplantation occur in ~10%–40% of cases, and most commonly occur at the anastomotic site.2,3

CP-related BSs are the most common nonsurgical BBSs, occurring in up to 13%–21% of patients.4,5 These CP-related strictures usually involve the distal CBD, and may be difficult to treat, due to fibrosis, scarring, and calcification of the bile-duct wall. Other causes of BBS include those related to PSC, choledocholithiasis, and autoimmune (IgG4) cholangiopathy (Table 1).

The clinical presentation of these BBSs may be varied, depending upon their etiology, location within the biliary tree, and degree of ductal narrowing. Accordingly, patients may be asymptomatic, have biochemical derangements in liver enzymes, or present with deep jaundice complicated by life-threatening cholangitis. Treatment methods and outcomes also vary, as described in the following sections.

Diagnosis

Identification of a suspected BBS requires correlation of a patient’s clinical history, imaging studies, including CT and/or MRI, and endoscopic findings. Histological assessment with cytology or histopathology is usually required to exclude malignancy.
Some cases may be diagnostically challenging, requiring a multidisciplinary approach and/or a prolonged period of clinical surveillance for exclusion of underlying occult malignancy.

Cross-sectional abdominal imaging can localize pathology, as well as provide a roadmap to plan therapeutic ERCP. MRCP and/or CT are often used for first-line imaging in patients with biliary obstruction. MRCP provides noninvasive, detailed images of the biliary tree, along with the location, length, and character of BSs prior to ERCP. MRCP features of BSs are characterized by regular, symmetrical, and short-segment narrowing. In contrast, malignant strictures are usually irregular, asymmetrical and of longer length, especially those $\geq 14$ mm. $^6$ Table 2 describes the most commonly used anatomical classification of BSs.

ERCP and/or endoscopic ultrasound-guided fine-needle aspiration or biopsy are used to establish a histological diagnosis. ERCP-guided methods include brush cytology or transpapillary forces biopsy. Both have high specificity but low sensitivity in diagnosing BS. A meta-analysis showed that sensitivity and specificity for diagnosis of malignant BS using brush cytology was 45% and 99%, respectively, and using transpapillary forces biopsy 48.1% and 99.2%, respectively. $^7$ Combining both modalities modestly increased sensitivity (59.4%), with a specificity of 100%. $^7$

To improve diagnostic yield, particularly for indeterminate strictures, adjunctive technologies, such as endoscopic ultrasound-guided fine-needle aspiration, cholangioscopy with biopsy, FISH, intraductal ultrasound, and confocal laser endomicroscopy, have been used. For benign-appearing strictures, clinical follow-up of at least 6 months with a benign course may help to confirm the diagnosis. This is supported by a prospective single-center follow-up study involving 104 patients with indeterminate BSs, which showed detection of biliary cancer was more common during the first 6 months of follow-up. $^8$ For patients with PSC, long-term patient follow-up is recommended, due to the risk of developing future biliary malignancy.

### Management

#### Endoscopic

ERCP is the first-line management option for most patients with BSs. Endoscopic access to the major papilla is a prerequisite. Endoscopic therapy for BSs is safe, effective, repeatable, and less invasive than other treatment options, such as percutaneous or surgical modalities. $^9$ Endoscopic methods to treat BSs include stricture dilatation using an over-the-wire balloon or bougie, followed by insertion of one or more plastic stents or a fully covered self-expandable metal stent (FCSEMS; Table 3). Plastic stents are changed periodically at intervals of 6–12 months to promote biliary drainage and stricture resolution. Recent data support the use of the FCSEMS for treatment of BSs. Reported advantages include high technical and clinical success, ease of insertion, and need of fewer endoscopic procedures for stricture resolution compared with multiple plastic stents. $^{10}$

In a large prospective multicenter study of 177 patients with BSs who received FCSEMS, stricture resolution was achieved in 135 (76.3%) patients. Endoscopic stent removal was achieved in all patients $(n=131)$ scheduled for stent removal, of which 124 (94.7%) had no serious removal-related adverse events. $^{11}$ In another study where FCSEMSs were placed for 6 months in patients with CP-associated BBS

### Table 1 Causes of benign biliary strictures

<table>
<thead>
<tr>
<th>Common</th>
<th>Less common</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postsurgical</td>
<td>Bile-duct ischemia</td>
</tr>
<tr>
<td>Liver transplantation</td>
<td>Vasculitis: SLE- and ANCA-associated</td>
</tr>
<tr>
<td>Cholecystectomy</td>
<td>Radiation therapy</td>
</tr>
<tr>
<td>Bilioenteric anastomosis</td>
<td>Portal biliopathy</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Post-radiofrequency ablation</td>
</tr>
<tr>
<td>Chronic pancreatitis</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Primary sclerosing</td>
<td>Post sphincterotomy</td>
</tr>
<tr>
<td>Cholangitis</td>
<td>Trauma</td>
</tr>
<tr>
<td>IgG4 cholangiopathy</td>
<td>Mirizzi syndrome</td>
</tr>
<tr>
<td></td>
<td>Parasitic infection</td>
</tr>
</tbody>
</table>

**Abbreviations:** SLE, systemic lupus erythematosus; ANCA, antineutrophil cytoplasmic antibody.

### Table 2 Bismuth classification for benign biliary strictures

<table>
<thead>
<tr>
<th>Bismuth class</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>$\geq 2$ cm distal to hepatic confluence</td>
</tr>
<tr>
<td>II</td>
<td>$&lt; 2$ cm distal to hepatic confluence</td>
</tr>
<tr>
<td>III</td>
<td>At the level of the hepatic confluence</td>
</tr>
<tr>
<td>IV</td>
<td>Involves the right or left hepatic duct</td>
</tr>
<tr>
<td>V</td>
<td>Extends into the left or right hepatic branch ducts</td>
</tr>
</tbody>
</table>

### Table 3 Recommended endoscopic treatments for causes of benign biliary strictures

<table>
<thead>
<tr>
<th>Condition</th>
<th>Dilatation</th>
<th>$\geq 1$ plastic stents</th>
<th>FCSEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP</td>
<td>–</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>PSC</td>
<td>Yes</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Liver transplantation</td>
<td>–</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Surgical injury</td>
<td>–</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>IgG4 cholangiopathy</td>
<td>–</td>
<td>Yes</td>
<td>–</td>
</tr>
<tr>
<td>Bilioenteric anastomosis</td>
<td>Yes</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Abbreviations:** CP, chronic pancreatitis; FCSEMS, fully covered self-expanding metal stent; PSC, primary sclerosing cholangitis.
refractory to prior placement of a 10 Fr plastic stent, stricture resolution was achieved in 70.6% (12 of 17). No stricture recurrence occurred in the eight patients who completed 2-year follow-up.12

Preparation
Prophylactic administration of intravenous antibiotics covering the Gram-negative bacteria Enterococcus and Pseudomonas are recommended for patients with hilar strictures, liver transplantation, and PSC, due to the potential for complex or multiple strictures complicating these conditions. However, for other patients, prophylactic antibiotics do not appear to prevent ERCP-related cholangitis.13,14 Incomplete biliary drainage is associated with an increased risk of bacteremia and cholangitis.15 Other factors associated with ERCP-related cholangitis in PSC include longer procedural duration and intraductal manipulation, eg, brush cytology, forceps biopsy, balloon dilatation, and cholangioscopy.

Endoscopic access
Therapeutic ERCP requires successful deep biliary cannulation with a wire. A biliary sphincterotomy facilitates placement of stents and assists endoscopic access for future ERCP, but does not appear to reduce the risk of post-ERCP pancreatitis after plastic or metal-stent insertion. Adjunctive techniques including precut papillotomy, double or single guide wire over a pancreatic stent may assist selective biliary cannulation in difficult cases. Hydrophilic 0.035-inch (0.889 mm) guide wires are most commonly used; however, smaller-diameter wires (0.018, 0.021, or 0.025 inches) with or without an angulated tip may improve success of traversing a tight or angulated stricture. When conventional guide-wire methods fail, such techniques as retraction on an inflated extraction balloon to straighten the BBS or cholangioscopy-assisted guide-wire placement may assist.16 Forceful advancement of the wire should always be avoided, as this risks creation of a false tract or perforation of the bile duct.

Dilatation
For severe fibrotic strictures, initial balloon or bougie dilatation may be required, followed by placement of one or more plastic stents or an FCSEMS. Very tight strictures sometimes may only be crossed by a balloon dilator. All dilators are passed over a guide wire traversing the stricture, visualized under fluoroscopy. The size of the dilator is guided by the width of the bile duct adjacent to the stricture. We recommend dilatation of the stricture for 30–60 seconds, or if using a balloon, until the stricture waist disappears. Forceful dilatation should be avoided, given the higher risk of ductal perforation, particularly in the early postoperative period (eg, within 4 weeks of liver transplantation) and/or while the patient is still on high-dose immunosuppression.17

Stricture recurrence after dilatation may be reduced by placement of a biliary stent.9,18 A systematic review of 19 studies showed treatment of anastomotic strictures after liver transplantation with plastic stents for longer periods predicted lower recurrence (OR 0.95, P=0.002), with overall stricture resolution in 86%.19 For CP-associated BBS, 90% stricture resolution was achieved with dilatation and placement of multiple 10 Fr plastic stents with regular stent change for 12 months. A systematic review of 25 studies found CP-related BBS treated by FCSEMS achieved greater resolution at 12 months than multiple plastic stents (77% vs 33%, respectively).20 For PSC-related strictures, dilatation alone usually achieves good long-term outcomes, even for dominant strictures.21

Stenting
Plastic stents
Extrahepatic BBS has traditionally been treated by placement of multiple plastic stents side by side across a stricture following dilatation. Long-term outcomes using this method may be equivalent or superior to those of surgical management, but with lower morbidity.22 A systematic review of 47 trials including 1,116 patients with extrahepatic BBS showed that placing multiple plastic stents had higher clinical success (94.3% vs 59.6%) and fewer adverse events (20.3% vs 36.0%) compared with placement of a single plastic stent, respectively.22

Treatment of BBS with plastic stents typically involves 3 monthly stent exchanges, with placement of an increasing number and/or diameter of stents for up to 12 months.23 Alternatively, the maximal number of stents can be inserted at the index ERCP, allowing reduced frequency of ERCP and stent exchange.24 Both approaches offer similar efficacy with regard to stricture resolution. Where multiple stents are used, duration of placement does not appear to affect incidence of symptomatic stent occlusion, and is similar for stents exchanged within 6 months compared to stents changed after longer periods.25

Metal stents
FCSEMSs are suitable for the treatment of BBS, as their silicone covering prevents tissue ingrowth and stent embedment into the duct wall. Conversely, uncovered SEMSs
are unsuitable for treatment of BBS, because reactive tissue ingrowth into the bare-wire lattice prevents their later removal. A stent-in-stent technique whereby an FCSEMS is placed temporarily within an embedded partially or uncovered SEMS is a potential salvage method of retrieval. A randomized trial comparing FCSEMSs and multiple plastic stents for the treatment of post-liver-transplantation BBS showed higher stricture resolution (81%–92% vs 76% – 90%), shorter stent placement time (3.8 vs 10.1 months), fewer endoscopic procedures (median 2.0 vs 4.5), fewer adverse events (10% vs 50%), and less cost for the FCSEMS group. Similar results were also reported in a separate recent randomized trial. FCSEMSs are unsuitable for treatment of hilar-located BBS, as a covered stent spanning the bifurcation may prevent biliary drainage from the opposite hepatic lobe. Cholecystitis is another potential complication of placing an FCSEMS in patients with an intact gallbladder, especially if the stent covers the cystic duct. The optimal FCSEMS indwelling duration is unknown, although recent evidence suggests placement of 6 months for post-liver-transplantation strictures and longer for BBS due to CP or cholecystectomy. A long FCSEMS indwelling time may increase the risk of cholangitis from stent occlusion or migration, and may hinder stent removal, as some embedding may occur from mucosal hyperplasia developing at the ends of the stent.

FCSEMSs are also at risk of stent migration, which may reduce treatment efficacy and increase risk of adverse events. Insertion of a double-pigtail plastic stent within an FCSEMS may help to anchor it, and has been shown to reduce migration and prolong stent indwelling. Lastly, a recent comparative study of 43 patients found FCSEMSs with an anchored flap design may have superior antimigration effects compared with those with a traditional flared proximal-end design.

Surgical

Surgery may be required for patients with refractory BBS or those who are noncompliant with endoscopic therapy. For example, a prospective study of patients with CP found those with pancreatic head calcifications were 17-times more likely to have failure of response to endoscopic stenting. Surgical treatment may provide better long-term outcomes for patients with persisting CP-associated BBS after more than three endoscopic procedures. Post-liver-transplantation nonanastomotic BBS also have lower treatment success following endoscopic drainage than those with anastomotic strictures.

As with endoscopic and percutaneous methods, the goal of operative management of BBS is establishment of bile flow to relieve jaundice and to prevent cholangitis, choledocholithiasis, and recurrent stricture. Surgical alternatives to repair of BBS include excision of strictures with end-to-end repair, Roux-en-Y hepaticojejunostomy, choledochojejunostomy, and choledoduodenostomy. The choice of repair depends on such variables as extent and location of BBS.

End-to-end anastomosis may be performed if the stricture is short, extrahepatic, and the ends can be opposed without

**Figure 1** Percutaneous transhepatic balloon dilatation of a proximal common bile-duct stricture.
tension. However, this approach is seldom used, given the inevitable loss of ductal length associated with fibrosis, as well as a high risk of postoperative stricture recurrence. Cholecodochoduodenostomy and Frey’s procedures are described for treatment of distal BSs in the setting of CP. For the majority of cases, a Roux-en-Y hepaticojejunostomy is the best choice of repair. With this technique, a Roux loop made of healthy, tension-free jejunum distal to the ligament of Treitz is passed to the hilum of the liver and anastomosed in an end-to-side fashion to the proximal bile duct. The procedure is safe and durable, with a rate of success of 80%–99% in the hands of experienced surgeons.

New techniques

Novel techniques, including magnetic compression anastomosis, intraductal radiofrequency ablation, and biodegradable stents, may be useful for selected BBS cases refractory to endoscopic or percutaneous methods. In a study of magnetic compression anastomosis, biliary recanalization was achieved in 89.7% (35 of 39) of patients with BBS due to surgical or traumatic etiologies. The average time from magnet approximation to removal was 57.4 days (range 13–182 days). Adverse events included one case of cholangitis and two cases of restenosis, which responded to endoscopic therapy.42

In a small study of nine patients with refractory BBS, intraductal bipolar radiofrequency ablation followed by balloon dilatation resulted in immediate stricture improvement in all patients. 43 Four patients had no recurrence of stricture after mean follow-up of 12.6 months. In a series of ten patients with refractory BBS, stricture resolution was achieved in all patients treated by a percutaneously placed biodegradable stent. No stent was visible at 6-month follow-up.44 In a series of 13 patients with BBS treated by endoscopically placed biodegradable stents, stricture resolution was 83% at 21-month follow-up.45 These methods are promising, but require further efficacy and safety evaluations prior to adoption into mainstream endoscopic practice.

Common etiologies

Chronic pancreatitis

Repeat inflammation and scarring of the pancreatic head in the setting of CP may result in formation of distal BSs (Figure 2). Endoscopic therapy is the recommended first-line treatment for CP-related CBD strictures, as it is less invasive than surgery. Nonetheless, CP-related strictures are more refractory to endoscopic treatment than other BBSs, especially if pancreatic calcifications are present.46 Placement of multiple plastic biliary stents has traditionally been used to treat CP-related BBS, although FCSEMS use is increasing because of their larger diameter, ease of placement, and need for fewer ERCP procedures.27,47

Systematic review data from 25 studies found endoscopic therapy to treat CP-associated BBS resulted in clinical

![Figure 2 (A, B) Examples of distal common bile-duct strictures associated with chronic pancreatitis. Note: Both strictures are relatively smooth with mild upstream biliary dilatation.](https://www.dovepress.com/doi-image.png)
success of 77% with covered SEMSs vs 33% with plastic stents at 12-month follow-up.\(^{20}\) The median number of ERCP procedures required to achieve clinical success was lower for SEMSs than plastic stents (1.5 vs 3.9, respectively; \(P=0.002\)).\(^{20}\) In another study of 60 patients with CP-related BBSs, patients were randomized to receive either a single 10 mm-diameter covered SEMS or three initial 10 Fr plastic stents, followed by placement of three more 10 Fr stents after 3 months. All stents were removed after 6 months. The 2-year stricture-free rate was 92% in patients receiving SEMSs and 90% in patients receiving plastic stents (\(P=0.405\)).\(^{27}\)

Overall, the data support the use of covered SEMSs as an effective therapy for the management of CP-related BBS, and these may be considered for first-line use over plastic stents. A small percentage of patients may not respond to endoscopic therapies, and will eventually require surgical biliary drainage.

**Primary sclerosing cholangitis**

PSC may result in formation of both BBSs and malignant BSs, an important but sometimes difficult-to-diagnose distinction. PSC-associated BBS results from fibrotic inflammation and may be multifocal, intrahepatic, or extrahepatic in location. Traditional brush cytology of strictures has modest sensitivity (43%) with high specificity (97%) for cholangiocarcinoma.\(^{48}\) FISH and confocal laser endomicroscopy may increase the sensitivity of cholangiocarcinoma diagnosis in PSC, particularly if cytology is atypical.\(^{30}\) In a meta-analysis, the sensitivity and specificity of FISH for diagnosis of cholangiocarcinoma in PSC was 68% and 70%, respectively.\(^{49}\) Direct cholangioscopic visualization of strictures aids targeted biopsies and passage of otherwise-inaccessible strictures. A prospective study assessing cholangioscopy in 47 patients with PSC found adequate sample quality in 95% of miniforceps biopsies, with sensitivity, specificity, accuracy, and negative predictive value of 33%, 100%, 96%, and 95%, respectively.\(^{50}\)

Endoscopic intervention is recommended in PSC for symptomatic patients with dominant BSs, as relief of biliary obstruction preserves hepatic function and may improve long-term survival.\(^{51,52}\) MRCP is recommended prior to ERCP to diagnose, locate, and characterize the dominant stricture. Routine prophylactic antibiotics are recommended before ERCP in patients with PSC to reduce the risk of cholangitis.\(^{52}\)

Endoscopic therapy for PSC-related BBS involves either balloon or bougie dilatation with or without placement of a temporary plastic stent. In a multicenter randomized study of 65 patients with PSC and dominant strictures, the cumulative recurrence-free rate was similar for balloon dilatation and temporary stent placement (maximum 2 weeks, respectively, 0.30 vs 0.34 at 24 months; \(P=1\)). Adverse events, such as pancreatitis and cholangitis, were significantly more frequent in the stent group than the dilatation group (45% vs 6.7%, respectively; \(P=0.001\)), suggesting that balloon-dilatation monotherapy is the preferred initial therapy in patients with PSC and dominant strictures.\(^{53}\)

**Liver transplantation**

BS after liver transplantation occurs at an incidence of 4%–43%, and may be classified as anastomotic or nonanastomotic.\(^{50}\) ABSs occur at the anastomotic site, typically as a single focal stricture and more frequently associated with living-donor livers than deceased-donor livers.\(^{3}\) Endoscopic therapy is effective and safe for ABS and the first-line treatment. Stricture dilatation followed by placement of multiple plastic biliary stents for ABS can achieve a high stricture resolution rate of 66.7%–100%, without the need for surgical intervention or retransplantation.\(^{3,54–56}\) Late-onset ABSs (≥6 months after transplantation) are likely to require more endoscopic interventions than those presenting in the early posttransplant period.\(^{57}\)

Covered SEMSs are increasingly used to treat ABS. A multicenter, prospective, uncontrolled study of 22 patients with ABS showed temporary placement of a SEMS for 2 months achieved long-term stricture resolution in 52%.\(^{58}\) A prospective randomized trial comparing FCSEMS to multiple plastic stents for ABS found a comparable stricture-resolution rate, but fewer endoscopic procedures were required using FCSEMS (2 vs 4.5, respectively; \(P=0.0001\)).\(^{55}\) Similar results were found in another randomized controlled study of 162 patients, where the stricture-resolution rate in patients receiving FCSEMS vs multiple plastic stents was 96.5% and 83%, respectively.\(^{59}\)

NABSs are defined as those occurring ≥5 mm proximally to the anastomosis and are associated with ischemic events. NABSs are characterized by multiple extrahepatic and/or intrahepatic ABSs with recurrent sludge or stone formation.\(^{30}\) Late-onset NABS, defined as those presenting ≥1 year after liver transplantation, more commonly occur in the peripheral biliary tree. NABSs are more resistant to endoscopic therapy than ABSs, requiring more episodes of stricture dilatation and longer periods of stenting, with higher rates of stricture recurrence. Success rates following endoscopic therapy for NABS range from 40% to 82%.\(^{60,61}\)
Surgical injury

LC is the most common cause of surgical bile-duct injury-related BBS, with an incidence of 0.5%.\(^1\) Traditional surgical repair, such as hepaticojejunostomy, was the preferred treatment of this type of postoperative BBS; however, endoscopic dilation followed by placement of multiple plastic stents is an accepted alternative, with both techniques resulting in similar clinical success.

For example, in a retrospective comparison study of 66 patients treated by endoscopic stenting and 35 patients treated by surgical therapy for postoperative BBS, long-term success rates were similar, with stricture recurrence occurring in 17% in both groups.\(^62\) In another retrospective study of 42 patients with postcholecystectomy BBSs, excellent or good long-term outcomes were achieved in 77.3% (17 of 22) patients treated surgically and 80% (16 of 20) patients treated endoscopically.\(^63\)

IgG\(_4\)-sclerosing cholangitis

IgG\(_4\)-associated cholangiopathy is an autoimmune inflammatory disease often associated with autoimmune pancreatitis and other systemic diseases. Patients may present with painless obstructive jaundice and intra- or extrahepatic strictures, which may mimic such conditions as PSC or cholangiocarcinoma (Figure 3). Corticosteroids are the first-line treatment of IgG\(_4\) cholangiopathy. In a prospective study of 23 patients with IgG\(_4\) cholangiopathy, a 100% response rate was reported after 6 weeks of prednisolone.\(^64\) In another study of 29 patients with symptomatic IgG\(_4\) cholangiopathy, 19 responded to steroids alone, 8

![Figure 3](image-url)  
**Figure 3** Patient with IgG\(_4\) cholangiopathy and painless obstructive jaundice.  
**Notes:** (A) Shouldered extrahepatic biliary stricture on MRCP with dilatation of the proximal biliary tree. (B) Tight proximal CBD stricture on ERCP. Appearances were suspicious for malignancy; however, cytology showed benign cells only. (C) A plastic biliary stent was placed for biliary drainage and relief from jaundice. (D) Resolution of biliary stricture after a 3-month course of oral prednisolone.  
**Abbreviations:** MRCP, magnetic resonance cholangiopancreatography; CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography.
responded to steroids and biliary stenting, and 2 required operative therapy. These data suggest that in most cases, biliary stenting may be unnecessary, but may be useful if there is significant biliary obstruction or cholangitis, prior to corticosteroid therapy.

**Biliary–enteric anastomotic stricture**

ERCP is challenging in patients with surgically altered anatomy, such as Roux-en-Y hepaticojejunostomy, gastric bypass, or following Whipple’s procedures. Reasons include length of the afferent limb, acute angulation of anastomosis, and adhesions limiting bowel mobility. Use of colonoscopy or balloon enteroscopy may improve endoscopic access to the major papilla in such patients.65,66 Lack of an elevator on these scopes does limit cannulation ability, particularly when the papilla cannot be viewed not en face. Where available, the short-type double-balloon enteroscope is preferred, as its working length of 152 cm is compatible with most ERCP catheters.30

A meta-analysis of 15 studies showed overall success rates of 80.9% for single-balloon enteroscopy to reach the biliary anastomosis of papilla, 69.4% for obtaining a cholangiogram, and 61.7% for achieving successful biliary intervention.67 Adverse events occurred in 6.5% of procedures, including pancreatitis (2.2%), perforation (0.8%), and major bleeding (0.4%). In another systematic review that included 945 enteroscopy-assisted ERCP procedures, cannulation was achieved in 92% of patients with anastomosis, overall success was 74%, and adverse events occurred in 3.4%.68 Balloon dilatation is effective for most biliary enteric anastomotic strictures (Figure 4), as shown in a study of 34 patients where balloon dilatation resulted in clinical success in 66% of patients.36

**Conclusion**

BBSs may arise from a variety of etiologies. Symptomatic patients may present with jaundice and/or cholangitis, which are indications for treatment. Endoscopic therapy by ERCP is the first-line treatment for BBS, given its relative clinical efficacy, safety, and cost-effectiveness compared with other modalities, such as percutaneous cholangiography or surgery. Typically, this involves stricture dilatation using a balloon or bougie catheter, followed by placement of one or more plastic stents side by side. Recent evidence also supports the use of FCSEMSs to treat BBS as an alternative to multiple plastic stents.

**Abbreviations**

ABS, anastomotic biliary stricture; BS, biliary stricture; BBS, benign biliary stricture; CBD, common bile duct; CP, chronic pancreatitis; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; FCSEMS, fully covered self-expanding metal stent; FISH, fluorescent in situ hybridization; LC, laparoscopic cholecystectomy; MRI, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography; NABS, nonanastomotic biliary stricture; PSC, primary sclerosing cholangitis; PTBD, percutaneous transhepatic biliary drainage; SEMS, self-expanding metal stent.

**Disclosure**

The authors report no conflicts of interest in this work.
References


For personal use only.

51. Thosani N, Banerjee S. Endoscopic retrograde cholangiopancreati-
Clinical and Experimental Gastroenterology

Publish your work in this journal

Clinical and Experimental Gastroenterology is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of gastroenterology in the clinic and laboratory. This journal is included on PubMed. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal

Dovepress

Clinical and Experimental Gastroenterology 2019:12